Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 6Carcinoid Tumor 5Neoplasms 4Carcinoma 3Vipoma 2Neoplasm Metastasis 2Intestinal Obstruction 2Carcinoma, Islet Cell 2Somatostatinoma 1Recurrence 1Prostatic Neoplasms 1Primary Inoperable Thymoma 1Pleural Effusion 1Peritoneal Neoplasms 1Malignant Carcinoid Syndrome 1Lymphangiomyoma 1Lymphangioleiomyomatosis 1Insulinoma 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Diarrhea 1Chylous Ascites 1Chylothorax 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Ascites 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 2pembrolizumab 1pasireotide 1lanreotide 1folfirinox 1copper dotatate CU-64 1arginyllysine 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Cytokines 1Cryotherapy 1Carboplatin 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastro-enteropancreatic neuroendocrine tumor × Octreotide × Clear all
NCT03972488 2026-01-21

NETTER-2

Advanced Accelerator Applications

Phase 3 Active not recruiting
226 enrolled 14 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡